+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rheumatoid Arthritis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts - 2023 to 2031

  • PDF Icon

    Report

  • 118 Pages
  • June 2023
  • Region: Global
  • Acute Market Reports
  • ID: 5851248
Description Jump to:
Rheumatoid arthritistherapeutics market expected to Grow at 4.2% by 2031, Rheumatoid arthritis is an autoimmune, inflammatory disease that causes chronic pain, swelling and loss in the functioning ability of joints. It occurs when the immune system attacks the synovium the inner lining of membranes that surrounds the joints. In some patients, the antibodies also damage some body systems including the skin, heart, eyes, lungs and blood vessels. Prevalence of rheumatoid arthritis widely varies in different geographic region, the lowest rates is observed in the Asian countries and higher rates among some American populations. According to Centers for Disease Control and Prevention (CDC), the prevalence of rheumatoid arthritis in the United States is approximately 0.6% of total population. Generally rheumatoid arthritis affects at twice the rate in women as compared to men. Mostly rheumatoid arthritis affects among those in their sixties. According to World Health Organization (WHO), prevalence varies between 0.3% and 1% and is more common in developed countries.

There are many approaches used in treatment of rheumatoid arthritis such as drug therapy, rehabilitation and physical therapy, nutrition, psychosocial interventions, alternative treatment approaches and surgical interventions. Global rheumatoid arthritis therapeutics market is segmented on the basis of drug type such as Non-biologics and Biologic agent (Adalimumab, Infliximab and others). Non-biologics is sub-segmented as NSAIDs (Diclofenac, Ibuprofen and others), Disease-modifying antirheumatic drugs (DMARDs) (Methotrexate, Leflunomide and others) and steroids (Cortisone or Prednisone). Biologics, DMARDs and steroids slows the joint damage from rheumatoid arthritis, while NSAIDs only reduces pain and inflammation. Biologics are used in treatment of moderate to severe rheumatoid arthritis when patient does not respond adequately to other treatments.

The major growth drivers of the global rheumatoid arthritis therapeutic market includes, increase in geriatric population that will increase prevalence of rheumatoid arthritis, launch of novel therapeutic agents, higher prevalence rates among some American native populations and insurance coverage for high cost specialty drugs in developed countries. However, factors such as, inadequate insurance coverage for certain drugs in developing countries, non-availability of the treatment and patent expiration of some blockbuster drugs are the main restraints for the rheumatoid arthritis therapeutic market.

Some key Players in global rheumatoid arthritis therapeutic market are, Pfizer Inc., Bristol Myers Squibb, Abbvie Inc., Ucb Pharma, Genentech, Janssen Pharmaceutical, Immunex Corp., Medac Pharma, Mallinckrodt, Novartis, Astrazeneca Pharma, MedImmune, Biogen, Eli Lilly And Company, Astellas Pharma, Roche, Vertex Pharmaceuticals And Other Notable Players.

This report offers:

  • An overview of the global markets for Rheumatoid Arthritis Therapeutics.
  • Qualitative assessment tools such as market drivers, challenges and future prospects.
  • Market competition scrutiny tools such as market share analysis, fractal map assessment.
  • Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
  • A general overview of the industry structure.
Company profiles highlighting key information about the major players operating in the global rheumatoid arthritis therapeutics market.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofRheumatoid Arthritis Therapeutics market are as follows:
  • Research and development budgets of manufacturers and government spendin.
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Rheumatoid Arthritis Therapeutics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Class
  • Infection altering Anti-rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-incendiary Drugs (NSAIDs)
  • Corticosteroids
  • Uric Acid Drugs
  • Others
Route of Administration
  • Oral
  • Parenteral
Sales Channel
  • Prescription
  • Over-the-counter Drugs

Region Segment (2021 - 2031; US$ Million)

  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Rheumatoid Arthritis Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Rheumatoid Arthritis Therapeutics market?
  • Which is the largest regional market for Rheumatoid Arthritis Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Rheumatoid Arthritis Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Rheumatoid Arthritis Therapeutics market worldwide?

This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Rheumatoid Arthritis Therapeutics Market
2.2. Global Rheumatoid Arthritis Therapeutics Market, By Class, 2022 (US$ Million)
2.3. Global Rheumatoid Arthritis Therapeutics Market, By Route of Administration, 2022 (US$ Million)
2.4. Global Rheumatoid Arthritis Therapeutics Market, By Sales Channel, 2022 (US$ Million)
2.5. Global Rheumatoid Arthritis Therapeutics Market, By Geography, 2022 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2022
3. Rheumatoid Arthritis Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Rheumatoid Arthritis Therapeutics Market Vendors
3.2. Strategies Adopted by Rheumatoid Arthritis Therapeutics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031
4. Rheumatoid Arthritis Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Rheumatoid Arthritis Therapeutics Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
5.3.1. Infection altering Anti-rheumatic Drugs (DMARDs)
5.3.2. Nonsteroidal Anti-incendiary Drugs (NSAIDs)
5.3.3. Corticosteroids
5.3.4. Uric Acid Drugs
5.3.5. Others
6. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
6.3.1. Oral
6.3.2. Parenteral
7. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
7.3.1. Prescription
7.3.2. Over-the-counter Drugs
8. North America Rheumatoid Arthritis Therapeutics Market, 2021-2031, USD (Million)
8.1. Market Overview
8.2. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
8.3. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
8.4. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
8.5.Rheumatoid Arthritis Therapeutics Market: By Region, 2021-2031, USD (Million)
8.5.1.North America
8.5.1.1. U.S.
8.5.1.1.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
8.5.1.1.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
8.5.1.1.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
8.5.1.2. Canada
8.5.1.2.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
8.5.1.2.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
8.5.1.2.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
8.5.1.3. Rest of North America
8.5.1.3.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
8.5.1.3.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
8.5.1.3.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
9. UK and European Union Rheumatoid Arthritis Therapeutics Market, 2021-2031, USD (Million)
9.1. Market Overview
9.2. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
9.3. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.4. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
9.5.Rheumatoid Arthritis Therapeutics Market: By Region, 2021-2031, USD (Million)
9.5.1.UK and European Union
9.5.1.1. UK
9.5.1.1.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
9.5.1.1.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.5.1.1.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
9.5.1.2. Germany
9.5.1.2.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
9.5.1.2.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.5.1.2.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
9.5.1.3. Spain
9.5.1.3.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
9.5.1.3.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.5.1.3.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
9.5.1.4. Italy
9.5.1.4.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
9.5.1.4.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.5.1.4.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
9.5.1.5. France
9.5.1.5.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
9.5.1.5.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.5.1.5.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
9.5.1.6. Rest of Europe
9.5.1.6.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
9.5.1.6.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.5.1.6.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
10. Asia Pacific Rheumatoid Arthritis Therapeutics Market, 2021-2031, USD (Million)
10.1. Market Overview
10.2. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
10.3. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.4. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
10.5.Rheumatoid Arthritis Therapeutics Market: By Region, 2021-2031, USD (Million)
10.5.1.Asia Pacific
10.5.1.1. China
10.5.1.1.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
10.5.1.1.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.5.1.1.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
10.5.1.2. Japan
10.5.1.2.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
10.5.1.2.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.5.1.2.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
10.5.1.3. India
10.5.1.3.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
10.5.1.3.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.5.1.3.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
10.5.1.4. Australia
10.5.1.4.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
10.5.1.4.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.5.1.4.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
10.5.1.5. South Korea
10.5.1.5.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
10.5.1.5.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.5.1.5.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
10.5.1.6. Rest of Asia Pacific
10.5.1.6.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
10.5.1.6.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.5.1.6.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
11. Latin America Rheumatoid Arthritis Therapeutics Market, 2021-2031, USD (Million)
11.1. Market Overview
11.2. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
11.3. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.4. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
11.5.Rheumatoid Arthritis Therapeutics Market: By Region, 2021-2031, USD (Million)
11.5.1.Latin America
11.5.1.1. Brazil
11.5.1.1.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
11.5.1.1.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.5.1.1.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
11.5.1.2. Mexico
11.5.1.2.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
11.5.1.2.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.5.1.2.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
11.5.1.3. Rest of Latin America
11.5.1.3.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
11.5.1.3.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.5.1.3.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
12. Middle East and Africa Rheumatoid Arthritis Therapeutics Market, 2021-2031, USD (Million)
12.1. Market Overview
12.2. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
12.3. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.4. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
12.5.Rheumatoid Arthritis Therapeutics Market: By Region, 2021-2031, USD (Million)
12.5.1.Middle East and Africa
12.5.1.1. GCC
12.5.1.1.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
12.5.1.1.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.5.1.1.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
12.5.1.2. Africa
12.5.1.2.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
12.5.1.2.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.5.1.2.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
12.5.1.3. Rest of Middle East and Africa
12.5.1.3.1. Rheumatoid Arthritis Therapeutics Market: By Class, 2021-2031, USD (Million)
12.5.1.3.2. Rheumatoid Arthritis Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.5.1.3.3. Rheumatoid Arthritis Therapeutics Market: By Sales Channel, 2021-2031, USD (Million)
13. Company Profile
13.1. Pfizer Inc.
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. Bristol Myers Squibb
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Abbvie Inc.
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. Ucb Pharma
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Genentech
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Janssen Pharmaceutical
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. Immunex Corp.
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Medac Pharma
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. Mallinckrodt
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. Novartis
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives
13.11. Astrazeneca Pharma
13.11.1. Company Overview
13.11.2. Financial Performance
13.11.3. Product Portfolio
13.11.4. Strategic Initiatives
13.12. MedImmune
13.12.1. Company Overview
13.12.2. Financial Performance
13.12.3. Product Portfolio
13.12.4. Strategic Initiatives
13.13. Biogen
13.13.1. Company Overview
13.13.2. Financial Performance
13.13.3. Product Portfolio
13.13.4. Strategic Initiatives
13.14. Eli Lilly And Company
13.14.1. Company Overview
13.14.2. Financial Performance
13.14.3. Product Portfolio
13.14.4. Strategic Initiatives
13.15. Astellas Pharma
13.15.1. Company Overview
13.15.2. Financial Performance
13.15.3. Product Portfolio
13.15.4. Strategic Initiatives
13.16. Roche
13.16.1. Company Overview
13.16.2. Financial Performance
13.16.3. Product Portfolio
13.16.4. Strategic Initiatives
13.17. Vertex Pharmaceuticals
13.17.1. Company Overview
13.17.2. Financial Performance
13.17.3. Product Portfolio
13.17.4. Strategic Initiatives
13.18. Other Notable Players
13.18.1. Company Overview
13.18.2. Financial Performance
13.18.3. Product Portfolio
13.18.4. Strategic Initiatives
List of Figures
Figure 1 Global Rheumatoid Arthritis Therapeutics Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Rheumatoid Arthritis Therapeutics Market: Quality Assurance
Figure 5 Global Rheumatoid Arthritis Therapeutics Market, By Class, 2022
Figure 6 Global Rheumatoid Arthritis Therapeutics Market, By Route of Administration, 2022
Figure 7 Global Rheumatoid Arthritis Therapeutics Market, By Sales Channel, 2022
Figure 8 Global Rheumatoid Arthritis Therapeutics Market, By Geography, 2022
Figure 9 Market Geographical Opportunity Matrix - Global Rheumatoid Arthritis Therapeutics Market, 2022
Figure 10 Market Positioning of Key Rheumatoid Arthritis Therapeutics Market Players, 2022
Figure 11 Global Rheumatoid Arthritis Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
Figure 12 Global Rheumatoid Arthritis Therapeutics Market, By Class, 2022 Vs 2031, %
Figure 13 Global Rheumatoid Arthritis Therapeutics Market, By Route of Administration, 2022 Vs 2031, %
Figure 14 Global Rheumatoid Arthritis Therapeutics Market, By Sales Channel, 2022 Vs 2031, %
Figure 15 U.S. Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 16 Canada Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 17 Rest of North America Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 18 UK Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 19 Germany Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 20 Spain Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 21 Italy Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 22 France Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 23 Rest of Europe Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 24 China Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 25 Japan Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 26 India Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 27 Australia Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 28 South Korea Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 29 Rest of Asia Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 30 Brazil Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 31 Mexico Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 32 Rest of Latin America Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 33 GCC Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 34 Africa Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
Figure 35 Rest of Middle East and Africa Rheumatoid Arthritis Therapeutics Market (US$ Million), 2021 - 2031
List of Tables
Table 1 Global Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 2 Global Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 3 Global Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 4 North America Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 5 North America Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 6 North America Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 7 U.S. Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 8 U.S. Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 9 U.S. Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 10 Canada Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 11 Canada Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 12 Canada Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 13 Rest of North America Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 14 Rest of North America Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 15 Rest of North America Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 16 UK and European Union Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 17 UK and European Union Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 18 UK and European Union Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 19 UK Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 20 UK Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 21 UK Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 22 Germany Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 23 Germany Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 24 Germany Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 25 Spain Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 26 Spain Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 27 Spain Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 28 Italy Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 29 Italy Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 30 Italy Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 31 France Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 32 France Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 33 France Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 34 Rest of Europe Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 35 Rest of Europe Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 36 Rest of Europe Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 37 Asia Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 38 Asia Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 39 Asia Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 40 China Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 41 China Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 42 China Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 43 Japan Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 44 Japan Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 45 Japan Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 46 India Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 47 India Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 48 India Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 49 Australia Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 50 Australia Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 51 Australia Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 52 South Korea Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 53 South Korea Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 54 South Korea Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 55 Latin America Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 56 Latin America Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 57 Latin America Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 58 Brazil Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 59 Brazil Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 60 Brazil Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 61 Mexico Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 62 Mexico Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 63 Mexico Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 64 Rest of Latin America Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 65 Rest of Latin America Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 66 Rest of Latin America Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 67 Middle East and Africa Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 68 Middle East and Africa Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 69 Middle East and Africa Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 70 Gcc Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 71 Gcc Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 72 Gcc Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 73 Africa Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 74 Africa Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 75 Africa Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)
Table 76 Rest of Middle East and Africa Rheumatoid Arthritis Therapeutics Market by Class, 2021-2031, USD (Million)
Table 77 Rest of Middle East and Africa Rheumatoid Arthritis Therapeutics Market by Route of Administration, 2021-2031, USD (Million)
Table 78 Rest of Middle East and Africa Rheumatoid Arthritis Therapeutics Market by Sales Channel, 2021-2031, USD (Million)

Companies Mentioned

  • Pfizer Inc.
  • Bristol Myers Squibb
  • Abbvie Inc.
  • Ucb Pharma
  • Genentech
  • Janssen Pharmaceutical
  • Immunex Corp.
  • Medac Pharma
  • Mallinckrodt
  • Novartis
  • Astrazeneca Pharma
  • MedImmune
  • Biogen
  • Eli Lilly And Company
  • Astellas Pharma
  • Roche
  • Vert

Related Topics

Related Reports

Rheumatoid Arthritis Therapeutics Market Report and Forecast 2025-2034 - Product Image

Rheumatoid Arthritis Therapeutics Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter), by Region, and Segment Forecasts, 2025-2033 - Product Image

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter), by Region, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Interleukin Inhibitors for Rheumatoid Arthritis Market - Global Forecast 2025-2030 - Product Image

Interleukin Inhibitors for Rheumatoid Arthritis Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Interleukin-6 Inhibitors for Rheumatoid Arthritis Market - Global Forecast 2025-2030 - Product Image

Interleukin-6 Inhibitors for Rheumatoid Arthritis Market - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Rheumatoid Arthritis Therapeutics - Global Strategic Business Report - Product Image

Rheumatoid Arthritis Therapeutics - Global Strategic Business Report

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.